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Isolated left ventricular noncompaction
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Background: Left ventricular noncompaction is very rare entity
with prevalence rate of 0.014–1.3% in western population. There is
no report from our country.
We report consecutive cases of isolated left ventricular noncom-
paction of SIX. We discuss historical, clinical, surface electrocar-
diogram, and echo-cardiographic features of this condition.
Result: One case has been linked with positive family history,
wherein father and son diagnose to have left ventricular noncom-
paction. In this series of cases, common localization of noncom-
pacted segments were in the apex and lateral wall of left
ventricular myocardium. Severe LV systolic dysfunction
(EF < 35%) seen in four cases. Grade II mitral regurgitation in four
cases and two cases had pulmonary artery hypertension.
Conclusion: High degree of suspicion in all cases of unexplained
severe left ventricular dysfunction is necessary to identify left
ventricular noncompaction.
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Background: Heart rate reduction has been proven to be of beneﬁt
in patients of chronic heart failure (HF). Despite advances in
management of HF, the morbidity and mortality remains high,
necessitating the development of novel therapeutic strategies.
Ivabradine is a selective sinus rate slowing agent which inhibits
the cardiac If current that is responsible for the spontaneous dia-
stolic depolarization in the sinus node. The role of ivabradine in HF
secondary to dilated cardiomyopathy (DCM) merits further study.
Methods: The study included 103 patients with DCM (mean age
47.9  14.8 years, NYHA class 3.2  0.4, BNP 742  489 pg/ml, LVEF
26.3  3.6%. Patients were randomized to receive ivabradine
(initiated at 2.5 mg BD titrated up to 7.5 mg BD at intervals of
2 weeks, titrated up to 7.5 mg BD, n = 52, Group 1) added to standard
therapy (beta blockers, ACE inhibitors, diuretics, n = 51, Group 2).
Functional class, BNP levels, and echocardiographic parameters
including LV volumes, LV end-systolic stress (LVESS), LVmass, LVwork,
and global LV strain were assessed at baseline, 3 months and 6
months follow-up.
Results: Baseline demographics including age, NYHA Class, BNP
levels, 6 min WT and MLWHF (Minnesota Living with HF ques-
tionnaire) scores were comparable between the two groups. There
was no difference in echocardiographic systolic and diastolic para-
meters amongst Groups 1 and 2 at baseline, including LVEF 26.06
 3.5% vs 26.7  3.1% ( p = 0.34), LVESS 205  44.3 vs 193  5.8
( p = 0.2), LV mass121.7  32 g vs126  39 g ( p = 0.5), LV work
531.2  146 vs 469  126 mmHg l/m ( p = 0.06), and LV global strain
10.4  1.3% vs10.1  1.6% ( p = 0.2). Themean dose of ivabradine
used was 12.1 mg  2.4 mg (range 5–15 mg); all patients tolerated
ivabradine well, except for rise in serum creatinine requiring with-
drawal of the drug in one patient.
3-months follow-up: Both groups had signiﬁcant improvement in mean
NYHA class (Gp 1 from 3.3  0.4 to 2  0, p = 0.001, Gp 2 from 3.2
 0.4 to 2  0.3, p = 0.03), 6 min walk test (Gp 1: 326  42 to 370
 38 m, p = 0.001, Gp 2: 336  76 to 364  77 m, p = 0.01), MLWHF
questionnaire (Gp 1: 74  14 to 58  11, p = 0.001, Gp 2: 78  8 to 65
 10, p = 0.001) and fall in BNP (Gp 1: 760  490 to 382  193 pg/ml,
p = 0.001, Gp 2: 724  492 to 420  289 pg/ml, p = 0.01). However, the
% change in 6 min WT, MLWHF and BNP was much higher in Ivabradine
group (+14%,21% and35%vs +9.4%,16% and30% respectively
with corresponding p values of 0.06, 0.02, 0.05). While both groups
demonstrated reduction in HR (95.6  12 to 80.3  7 bpm, p = 0.001 in
ivabradine group, 94.6  9 to 87.3  7 bpm, p = 0.001 in controls), the
% change was signiﬁcantly higher in the ivabradine group (15% vs
10.2%, p = 0.03). No signiﬁcant reduction in systolic or diastolic BP
was seen in the ivabradine group.
At 3 months, amongst those receiving ivabradine, there was sig-
niﬁcant improvement in indexed LV end-systolic (LVESVi, 86  19
to 73  15 ml/m2, p = 0.001) and LV end-diastolic volumes (LVEDVi
117  34 to 103  19 ml/m2, p = 0.001), MPI (0.82  1.2 to 0.7  0.1,
p = 0.001) and LVEF (26  3.5 to 29  3.6%, p = 0.001). The % change
in LVESVi, LVEDVi, MPI and LVEF was 15%, 15%, +11%, and
+12.2%, respectively. In contrast, amongst controls there was no
signiﬁcant change in LVESVi (83  20 to 81  21 ml/m2, p = 0.2),
LVEDVi (113  27 to 113  24 ml/m2, p = 0.9), MPI (0.79  1 to 0.75
 0.1, p = 0.06) and LVEF (26.7  3.7 to 26.7  4.5%, p = 0.9).
6months follow-up: At 6months, while both group of patients had
further improvement in NYHA class, 6 minWT, MLWHF score and
fall in BNP, the % change in all parameters was signiﬁcantly higher
with ivabradine group – (6 minWT: (19% vs 11.6%, p = 0.01, MLWHF
score 22% vs 16%, p = 0.01, fall in BNP 64% vs 31%, p = 0.001). At 6
months, the % reduction in HR was also signiﬁcantly greater in
those on ivabradine (19.5% vs 7.5%, p = 0.001). Importantly,
96.1% achieved HR < 70/min at 6 months on therapy with ivabra-
dine as compared to only 25.6% of those on standard treatment.
Age
(years)
Sex Clinical symptoms Localization of
non–compaction
LVF
EF-%
MR PA
Pressure
Inter
trabecular
recesses
Cardiomegaly
(chest X-ray)
ECG
Dyspnea Palpitation
25 M Class IV No Apex and lateral 30 Mild Normal 8 Yes Normal
56 M Class II No Apex and lateral 36 Mild Normal 6 Yes Normal
39 M Class II No Apex only 50 Trivial Normal 3 No Normal
39 M Class II No Apex only 48 Trivial 50 8 No Normal
65 F Class IV No Apex, lower end of
septum and lateral wall
32 Mild Normal 10 No Normal
74 F Class II No Apex and lateral 35 Mild 57 15 Yes Normal
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Only patients in Ivabradine demonstrated further improvement in LVESVi
(73  15 ml/m2 to 62  15 ml/m2, p = 0.001), LVEDVi (103  19 ml/
m2 to 95  18 ml/m2, p = 0.001), MPI (23% vs 2.7%, p = 0.001), LVEF
(29  3.6 to 34.5  5.4%, p = 0.001) and LVGlobal Strain (13.3  1.6 to
20.2  4.4%, p = 0.001) while those in the control group did not
show any further change. Parameters like E/A, E/A VTI, MPI, E/E'
septal and E/E' lateral showed sustained improvement at 6months only in
the ivabradine group – E/A (1.5  0.5 to 1.1  0.3, p = 0.001), E/A VTI
(1.6  0.5 to 1.1  0.3, p = 0.001), E/e' septal (11.6  3.3 to 9.5  2.2,
p = 0.001), E/e' lateral (11.6  3.2 to 9.8  2.5, p = 0.001).
On multivariate analysis, heart rate reduction was a stronger pre-
dictor of improvement in LVEF ( p = 0.03) than ivabradine treatment
( p = 0.5). Change in HR signiﬁcantly correlated with improvement
in NYHA class (r = +0.4, p = 0.01), fall in BNP levels (r = 0.4,
p = 0.001), better EF (r = 0.38, p = 0.001) and reduction in global
LV strain (r = +0.28, p = 0.03) at 6 months.
Conclusion: Ivabradine added to standard therapy in patients of
DCM with chronic HF produces greater % change in all assessed
parameters including functional class and echocardiographic
parameters especially global LV strain. Ivabradine therapy was
four times more likely to result in HR reduction to <70 bpm at 6
months. Heart rate manipulation with ivabradine may play an
important role in the management of such patients.
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A 24-year-old male patient presented with mild epigastric pain for
2 days and fever for one week. Electrocardiogram of the patient
was suggestive of ventricular tachycardia with a heart rate of 200/
min. Immediately, the patient was injected IV amiodarone 150 mg
as bolus dose. The patient became dyspnoeic and developed frank
pulmonary edema after sometime and had to be managed with
mechanical ventilator support. 2D echocardiography suggestive of
dilated cardiomyopathy which reversed as the patient improved.
The brucella IgM antibodies titres were 3.51 (positive > 1.1). Dilated
cardiomyopathy was caused by Brucella myocarditis which led to
ventricular tachycardia on admission, cardiogenic shock with sub-
sequent development of pulmonary edema and acute renal failure.
The cardiogenic shock led to ischemic hepatitis which was possi-
bly accentuated further by the bolus dose of amiodarone. Thus,
ﬁnal diagnosis of Brucella myocarditis with ischemic hepatitis and
acute kidney injury was made.
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Background: The goal of this study was to evaluate if red cell
distribution width (RDW) can serve as a relatively inexpensive
diagnostic marker in cases of heart failure (HF) in India, where
diagnostic markers such as N Terminal-Pro Brain Natriuretic Pep-
tide (NTP BNP) are expensive.
Methods: This was an cross-sectional observational study con-
ducted from June 2012 to June 2014 in a tertiary care hospital, in
which participants aged ≥18 years, after informed consent was
divided into two groups: Cases – 100 patients with HF diagnosed on
the basis of clinical examination, X-ray chest and Echodoppler and
Controls – 100 patients without HF. Those with conditions which
elevate RDW like anemia, arthritis, neoplasia, hypothyroidism,
liver disease, and inﬂammatory bowel disease were excluded.
SYSMEX KX 21 Automated Hematology Analyserwas used to generate
the complete blood count (CBC) report from which RDW was
compared between the two groups to evaluate its utility as an
independent marker for HF.
Results: Out of the 100 patients of HF, 47 had HF with reduced
ejection fraction (HFREF) and 53 had HF with preserved ejection
fraction (HFPEF). Themean RDWwas signiﬁcantly higher in the HF
patients (53.85  5.39 ﬂ) than controls (42.21  1.66 ﬂ). It was also
found to be signiﬁcantly higher in both subgroups – HFREF (56.96
 5.18 ﬂ) and HFPEF (51.10  3.88 ﬂ) than that in controls. Using the
Spearman's Rho calculator, the value of ‘‘r’’ between RDW and
LVEF is 0.55996 and the two-tailed value of p is 0 which was
statistically signiﬁcant.
Conclusion: RDW is a readily available and relatively inexpensive
test which can be carried out in the HF-population. BothHFREF and
HFPEF patients were found to have signiﬁcantly higher RDW than
controls. Understanding how and why this marker is associated
with HF may provide novel insights into HF pathophysiology.
Further investigation is necessary to determine the pathological
mechanism of the relationship and its prognostic signiﬁcance.
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Introduction: Severe pulmonary artery hypertension (PAH) in
infants is rare presentation without congenital heart disease
(CHD). Cardiac beriberi is often a missed diagnosis and is still
common. Thiamine supplements in unexplained congestive heart
failure (CHF) with severe PAH in a patient from poor socio eco-
nomic (SE) status may be life saving.
Materials and methods: A total of 25 infants (male 18, female 7)
were found to have unexplained severe PAH during period of June
2012 to June 2015were included. All infantswere exclusively breast
fed belonging to low SE strata with their mothers from predomi-
nant rice eating population. Infants with CHD were excluded.
Presentation was poor feeding, excessive cry and/or respiratory
distress. 2D Echo done showed severe PAH and RV dysfunction in
all; 2 patients had associated pericardial and pleural effusion.
Diagnosis of cardiac beriberi was made and thiamine supplement
were started immediately. No other PAH medications were given.
Results:The average age of presentationwas 3.5months (range 1–6
months); weight 4.3 kg (2.8–6.5 kg). Arterial blood gas (ABG) analysis
showed high lactate levels (mean 6.4, range 3.4–17 mmol/l) at pre-
sentation. Mean PA pressures were 74 mmHg (range 50–110mmHg)
at admission. The lactate levels were higher in infants less than
three-month age (n = 10) when compared with older infants (n = 15)
between 3-month and 6-month age group (lactate 9.6 mmol/l vs
4.2 mmol/l respectively, p < 0.05). The infants presenting before
threemonths had severe CHF and two infants presentedwith acute
gasping state with severe lactic acidosis requiring mechanical ven-
tilation. The response of thiamine supplement was rapid, ABG
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